Publications by authors named "Christopher Bertini"
Article Synopsis
- * COVID-19 leads to increased hospitalization and mortality rates among immunocompromised patients, highlighting the need for better treatment approaches tailored to this group.
- * The effectiveness of current interventions like vaccines and monoclonal antibodies is inconsistent for these patients, indicating a critical need for more research to address these gaps in knowledge.
Bronchiolitis obliterans syndrome (BOS) after hematopoietic cell transplantation (HCT) is associated with substantial morbidity and mortality. Quantitative computed tomography (qCT) can help diagnose advanced BOS meeting National Institutes of Health (NIH) criteria (NIH-BOS) but has not been used to diagnose early, often asymptomatic BOS (early BOS), limiting the potential for early intervention and improved outcomes. Using pulmonary function tests (PFTs) to define NIH-BOS, early BOS, and mixed BOS (NIH-BOS with restrictive lung disease) in patients from 2 large cancer centers, we applied qCT to identify early BOS and distinguish between types of BOS.
View Article and Find Full Text PDFImmunocompromised hosts, which encompass a diverse population of persons with malignancies, human immunodeficiency virus disease, solid organ, and hematologic transplants, autoimmune diseases, and primary immunodeficiencies, bear a significant burden of the morbidity and mortality due to coronavirus disease-2019 (COVID-19). Immunocompromised patients who develop COVID-19 have a more severe illness, higher hospitalization rates, and higher mortality rates than immunocompetent patients. There are no well-defined treatment strategies that are specific to immunocompromised patients and vaccines, monoclonal antibodies, and convalescent plasma are variably effective.
View Article and Find Full Text PDFArticle Synopsis
- Survivors of SARS-CoV-2 pneumonia, particularly cancer patients, often experience lasting respiratory symptoms and interstitial lung abnormalities (ILAs) following their infection, but the risk factors for these conditions are not well understood.
- In a study of 140 patients from cancer centers, around 70% of participants had ILAs just 3 months after hospital discharge, with a notable percentage still experiencing symptoms at 6 months.
- Higher pneumonia severity scores at hospital admission were linked to a greater likelihood of developing persistent ILAs, suggesting that both the severity of initial illness and age can influence respiratory recovery in these patients.
Immunocompromised hosts, which encompass a diverse population of persons with malignancies, human immunodeficiency virus disease, solid organ, and hematologic transplants, autoimmune diseases, and primary immunodeficiencies, bear a significant burden of the morbidity and mortality due to coronavirus disease-2019 (COVID-19). Immunocompromised patients who develop COVID-19 have a more severe illness, higher hospitalization rates, and higher mortality rates than immunocompetent patients. There are no well-defined treatment strategies that are specific to immunocompromised patients and vaccines, monoclonal antibodies, and convalescent plasma are variably effective.
View Article and Find Full Text PDF